10,326 Shares of Ascendis Pharma A/S $ASND Bought by Ethic Inc.

Ethic Inc. acquired a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 10,326 shares of the biotechnology company’s stock, valued at approximately $2,353,000.

Other institutional investors have also modified their holdings of the company. Chicago Partners Investment Group LLC boosted its stake in shares of Ascendis Pharma A/S by 2.3% in the third quarter. Chicago Partners Investment Group LLC now owns 2,316 shares of the biotechnology company’s stock worth $564,000 after buying an additional 52 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in Ascendis Pharma A/S by 34.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 69 shares in the last quarter. ProShare Advisors LLC grew its stake in shares of Ascendis Pharma A/S by 5.6% during the 3rd quarter. ProShare Advisors LLC now owns 2,134 shares of the biotechnology company’s stock worth $486,000 after purchasing an additional 113 shares during the period. AlphaCentric Advisors LLC grew its stake in shares of Ascendis Pharma A/S by 2.6% during the 3rd quarter. AlphaCentric Advisors LLC now owns 4,706 shares of the biotechnology company’s stock worth $1,072,000 after purchasing an additional 121 shares during the period. Finally, Allworth Financial LP increased its holdings in shares of Ascendis Pharma A/S by 103.4% during the 2nd quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 122 shares in the last quarter.

Ascendis Pharma A/S Stock Up 1.0%

ASND stock opened at $259.28 on Thursday. Ascendis Pharma A/S has a 52 week low of $188.07 and a 52 week high of $282.15. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. The firm has a 50-day simple moving average of $242.59 and a 200-day simple moving average of $239.48. The stock has a market capitalization of $16.17 billion, a P/E ratio of 20.11 and a beta of 0.40.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. The firm had revenue of $387.22 million for the quarter, compared to analysts’ expectations of $376.75 million. Equities analysts forecast that Ascendis Pharma A/S will post 3.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

ASND has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $300.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, September 25th. Wall Street Zen raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Sunday. TD Cowen reissued a “buy” rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. BMO Capital Markets restated an “outperform” rating on shares of Ascendis Pharma A/S in a research report on Thursday, September 10th. Finally, Royal Bank Of Canada lifted their price target on Ascendis Pharma A/S from $280.00 to $290.00 and gave the company an “outperform” rating in a research note on Friday, August 14th. Nineteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and an average target price of $305.95.

Insider Transactions at Ascendis Pharma A/S

In other news, Director Jean-Jacques Bienaimé purchased 2,000 shares of Ascendis Pharma A/S stock in a transaction dated Friday, August 14th. The shares were purchased at an average price of $246.33 per share, with a total value of $492,660.00. Following the transaction, the director owned 2,900 shares in the company, valued at $714,357. This represents a 222.22% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mads Bodenhoff sold 3,000 shares of Ascendis Pharma A/S stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the sale, the senior vice president owned 3,000 shares in the company, valued at $810,570. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 40.00% of the stock is owned by insiders.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.